Alpa Desai, MD
Pulmonary Disease · Stony Brook, NYNPI 1548428618
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $204,515 of the $237,217 with a category attached, or 86.2%. 17 manufacturers reported payments, led by Boehringer Ingelheim at 42.0% of the total. Reporting peaked in 2019 at $70,382 and has fallen 89.0% since, to $7,719 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $895.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$100K
- Mallinckrodt Hospital Products Inc.$77K
- Mallinckrodt Enterprises LLC$46K
- Genentech USA, Inc.$11K
- ANI Pharmaceuticals, Inc.$2K
- United Therapeutics Corporation$498
- plus $481 from 11 others
Across 53 payments — averaging $4252.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$131K
- Boehringer Ingelheim$50K
- Amgen$25K
- Roche Products Limited$14K
- Boehringer Ingelheim International GmbH$6K
What the payments were for
- Consulting fees$14,0536%
- Speaking & faculty fees$204,51586%
- Travel & lodging$9,0854%
- Food & beverage$9,5014%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 127 | $99,597 |
| Mallinckrodt Hospital Products Inc. | 56 | $76,624 |
| Mallinckrodt Enterprises LLC | 35 | $46,412 |
| Genentech USA, Inc. | 16 | $11,313 |
| ANI Pharmaceuticals, Inc. | 4 | $2,292 |
| United Therapeutics Corporation | 6 | $498 |
| GSK | 5 | $102 |
| Merck | 5 | $100 |
| Genentech, Inc. | 1 | $50 |
| Chiesi USA, Inc. | 3 | $48 |
| Astellas Pharma US Inc | 1 | $36 |
| Melinta Therapeutics, LLC | 1 | $30 |
| Boston Scientific | 1 | $26 |
| Mylan Specialty L.p. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Insmed, Inc. | 1 | $21 |
| AbbVie | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$119,617
- OFEV$57,766
- Esbriet$4,767
- PURIFIED CORTROPHIN GEL$2,250
- TYVASO$149
How this compares
$237,217 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 76 | $1,166,169 |
| Pirfenidone | 23 | $176,444 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $89,028 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $35,847 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $20,401 |
| Spiriva RespimatTiotropium Bromide | 12 | $14,134 |
| Mycophenolate Mofetil | 37 | $12,829 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $11,477 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $8,094 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $5,014 |
| DalirespRoflumilast | 11 | $4,476 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,688 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $2,182 |
| Fluticasone Propionate | 34 | $926 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $99,597 | $1,200,704114 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $102 | $140,041207 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Stony Brook
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.